Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Mental disorders in type 2 diabetes].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2021

Same author

The effect of advanced recovery room care on postoperative outcomes in moderate-risk surgical patients: a multicentre feasibility study.

Anaesthesia·2020

Same author

Comment on the consensus report on the management of hyperglycaemia in Type 2 diabetes by the American Diabetes Association and the European Association for the Study of Diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019

Same author

Technetium-99m-labeled lapachol as an imaging probe for breast tumor identification.

Revista espanola de medicina nuclear e imagen molecular·2019

Same author

The role of <sup>18</sup>F-FDG PET/CT imaging in the diagnosis of ovarian cancer.

Revista espanola de medicina nuclear e imagen molecular·2018

Same author

Weight-adapted iodinated contrast media administration in abdomino-pelvic CT: Can image quality be maintained?

Radiography (London, England : 1995)·2018

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

PET imaging in endocrine tumours.

S Khan¹, C Lloyd, T Szyszko

¹Department of Nuclear Medicine, Hammersmith Hospital and Imperial College, London, UK.

Minerva Endocrinologica

|April 17, 2008

Summary

Positron emission tomography (PET) using Gallium-68 tracers offers a superior, cost-effective, and accessible alternative to (18)F-fluoro-deoxy-D-glucose (FDG) and carbon-11 radiopharmaceuticals for endocrine tumor assessment.

More Related Videos

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of ⁶⁸Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Related Experiment Videos

Last Updated: Jul 5, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of ⁶⁸Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Area of Science:

Nuclear medicine and molecular imaging
Endocrinology and oncology

Background:

Traditional PET imaging for endocrine tumors relied on (18)F-fluoro-deoxy-D-glucose (FDG), which is suboptimal for slow-growing, differentiated tumors.
Carbon-11 labeled radiopharmaceuticals are effective but limited by short half-lives and the need for on-site cyclotrons.

Purpose of the Study:

To evaluate Gallium-68 as a novel PET tracer for endocrine tumor assessment.
To highlight the advantages of Gallium-68 over existing PET agents in terms of accessibility and cost-effectiveness.

Main Methods:

Review of existing literature on PET tracers for endocrine tumors, focusing on FDG, carbon-11, and Gallium-68.
Discussion of the characteristics of Gallium-68, including its generator-based production, short half-life, and labeling flexibility.

Main Results:

Gallium-68, produced from a generator, is economical and independent of cyclotrons, overcoming limitations of carbon-11 tracers.
Its ability to be labeled with various peptides and antibodies makes it ideal for PET imaging of diverse endocrine tumors.
Gallium-68 shows promise beyond gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) and pheochromocytoma.

Conclusions:

Gallium-68 PET offers a practical and versatile imaging solution for a broader range of endocrine tumors.
This tracer represents a significant advancement in the molecular imaging of endocrine malignancies.